GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xvivo Perfusion AB (FRA:3XV) » Definitions » Forward PE Ratio

Xvivo Perfusion AB (FRA:3XV) Forward PE Ratio

: 117.65 (As of Today)
View and export this data going back to 2020. Start your Free Trial

Xvivo Perfusion AB's Forward PE Ratio for today is 117.65.

Xvivo Perfusion AB's PE Ratio without NRI for today is 105.03.

Xvivo Perfusion AB's PE Ratio for today is 105.03.


Xvivo Perfusion AB Forward PE Ratio Historical Data

The historical data trend for Xvivo Perfusion AB's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xvivo Perfusion AB Annual Data
Trend 2020-08 2022-12 2023-12 2024-04
Forward PE Ratio
277.78 81.30 73.53 114.94

Xvivo Perfusion AB Quarterly Data
2022-03 2022-06 2022-09 2022-12 2023-03 2023-06 2023-09 2023-12 2024-03
Forward PE Ratio 204.08 151.52 59.17 81.30 105.26 111.11 63.29 73.53 97.09

Competitive Comparison

For the Medical Devices subindustry, Xvivo Perfusion AB's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB Forward PE Ratio Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Forward PE Ratio falls into.



Xvivo Perfusion AB Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Xvivo Perfusion AB  (FRA:3XV) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Xvivo Perfusion AB Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Xvivo Perfusion AB's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Xvivo Perfusion AB (FRA:3XV) Business Description

Traded in Other Exchanges
Address
Massans gata 10, P.O. Box 53015, Gothenburg, SWE, SE-400 14
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of all major organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments namely, Thoracic: Sales of lung and heart transplant products, Abdominal: Sales of liver and kidney transplant products. Services: Revenue from sales of services in organ recovery (carried out by subsidiary STAR Teams Inc.). The majority of revenue is derived from the Thoracic segment. Geographically, the majority is from the United States.

Xvivo Perfusion AB (FRA:3XV) Headlines

No Headlines